Group 1 - Nestlé, headquartered in Switzerland, has recalled baby formula in 37 countries due to potential bacterial contamination [1] - The contaminated ingredient, arachidonic acid (ARA), was sourced from a Chinese supplier, one of the world's top three ARA producers [1] - The specific name of the supplier has not been disclosed by Nestlé [1] Group 2 - China has requested Nestlé (China) to recall relevant batches of the affected products [1] - Major ARA producers in China include DSM, Cabio, and Runke Biotech, with DSM and Runke Biotech stating they are not involved in the incident [1] - Attention is now focused on Cabio, a biotech company based in Wuhan, as a potential source of the contamination [1] Group 3 - Lactalis, a private company in France, also recalled certain baby formulas in January due to contamination with vomiting-type enterotoxin [1] - The French Ministry of Agriculture announced that Lactalis's recall is related to the same Chinese raw material supplier as Nestlé's case [1]

Group 1 - Nestlé has announced a precautionary recall of infant formula products due to quality issues with arachidonic acid (ARA) oil from a major supplier, although no related illness cases have been confirmed [1] - ARA is a long-chain polyunsaturated fatty acid that is important for brain development in infants and is commonly added to most infant formulas on the market [1] - The CEO of Nestlé, Philipp Navratil, has publicly apologized to consumers regarding the recall [1] Group 2 - According to national standards, ARA is classified as an "optional ingredient" in infant formula, with a maximum allowable content of 80 mg per 100 kcal [2] - The addition of ARA and DHA in infant formulas has become a market norm due to clinical evidence supporting their benefits for brain and nervous system development in infants [3] - The standards for nutrient addition in infant formula are continuously updated to ensure higher quality products, with the aim of promoting comprehensive growth and development in infants [3]

Core Viewpoint - The Shanghai Stock Exchange has issued a regulatory letter to Jiabiyou, urging the company to respond promptly and fulfill its information disclosure obligations, potentially linked to a recent global recall of infant formula by Nestlé [1][2]. Group 1: Regulatory Actions - Jiabiyou received a regulatory letter from the Shanghai Stock Exchange on January 12, 2026, regarding the need to respond to the exchange's inquiries and fulfill disclosure obligations [2]. - The specific content of the regulatory letter from the Shanghai Stock Exchange remains unclear, but it is speculated to be related to Nestlé's recent recall of infant formula products [2]. Group 2: Market Impact and Company Response - Following the recall incident, Jiabiyou's stock price fell by 14.62% to 20.5 CNY per share on January 8, marking a nine-month low since April 10, 2025 [5]. - As of January 12, 2026, Jiabiyou's stock was trading at 20.45 CNY per share, with a total market capitalization of 3.442 billion CNY [5]. Group 3: Company Profile and Product Information - Jiabiyou is identified as the largest supplier of Arachidonic Acid (ARA) in China and a significant player in the international market [4]. - The company's main products include ARA, Docosahexaenoic Acid (DHA), β-Carotene (BC), N-Acetylneuraminic Acid (SA), and other related compounds [4].

Core Insights - The Ministry of Industry and Information Technology of China has officially released the first batch of the "Biomanufacturing Pilot Capability Construction Platform List," with Jia Bi You Biotechnology (Wuhan) Co., Ltd. being recognized for its strong technological foundation and industrial application capabilities in biomanufacturing [1][2] - Biomanufacturing has been elevated to a national strategic level, identified as a key growth point in the "14th Five-Year Plan," and is expected to play a crucial role in supporting China's dual carbon goals and green transformation [2][6] - Jia Bi You is positioned as a "full-chain player" in the biomanufacturing sector, having successfully industrialized key nutritional ingredients and expanded its product line to include high-value items such as DHA and HMOs [3][6] Industry Context - The emphasis on biomanufacturing in the "14th Five-Year Plan" reflects the need for China to enhance its economic structure and address global industrial competition, particularly in high-value areas like green manufacturing and functional molecules [2][4] - The selection of "symbolic projects" by regulatory authorities aims to identify companies that can represent China's competitiveness in high-end nutritional raw materials and green manufacturing [2][4] Company Developments - Jia Bi You has been recognized for its innovative capabilities, having its product 2'-fucosyllactose (2'-FL) selected as a "symbolic product" in biomanufacturing, alongside its inclusion in the high-performance bioreactor innovation list [3][6] - The company is actively implementing an "AI + synthetic biology" strategy, enhancing its research and manufacturing processes through automation and advanced technologies [4][5] - Jia Bi You has established an intelligent research platform and is developing proprietary computational tools to optimize its biomanufacturing processes, significantly improving efficiency and product quality [5][6] Strategic Positioning - Jia Bi You is strategically aligned with national policies, having developed a platform-based approach that integrates AI and synthetic biology to enhance its production capabilities [7][8] - The company has proactively engaged in regional industrial planning, positioning itself to benefit from favorable policies and market opportunities in the biomanufacturing sector [7][8]